CN110129446A - 用于人体her2基因扩增状态检测的组合套装 - Google Patents
用于人体her2基因扩增状态检测的组合套装 Download PDFInfo
- Publication number
- CN110129446A CN110129446A CN201910461395.8A CN201910461395A CN110129446A CN 110129446 A CN110129446 A CN 110129446A CN 201910461395 A CN201910461395 A CN 201910461395A CN 110129446 A CN110129446 A CN 110129446A
- Authority
- CN
- China
- Prior art keywords
- seq
- dna
- her2
- segment
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101150054472 HER2 gene Proteins 0.000 title claims abstract description 112
- 108700020302 erbB-2 Genes Proteins 0.000 title claims abstract description 112
- 238000001514 detection method Methods 0.000 title claims abstract description 65
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 84
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 72
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 72
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 64
- 108020004414 DNA Proteins 0.000 claims description 129
- 239000000523 sample Substances 0.000 claims description 86
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 53
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 53
- 238000003752 polymerase chain reaction Methods 0.000 claims description 26
- 230000000295 complement effect Effects 0.000 claims description 25
- 230000002018 overexpression Effects 0.000 claims description 24
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 21
- 238000012408 PCR amplification Methods 0.000 claims description 20
- 210000001519 tissue Anatomy 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 14
- 108700026244 Open Reading Frames Proteins 0.000 claims description 11
- 239000002773 nucleotide Substances 0.000 claims description 11
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- 230000003321 amplification Effects 0.000 claims description 10
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 10
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 8
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 8
- 210000002230 centromere Anatomy 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 239000000284 extract Substances 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 2
- 108091093088 Amplicon Proteins 0.000 description 8
- 108010067770 Endopeptidase K Proteins 0.000 description 7
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229940087305 limonene Drugs 0.000 description 3
- 235000001510 limonene Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000218636 Thuja Species 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 108091092742 A-DNA Proteins 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- HMFHBZSHGGEWLO-TXICZTDVSA-N beta-D-ribose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-TXICZTDVSA-N 0.000 description 1
- 229940017687 beta-d-ribose Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000001343 fallopian tube carcinoma Diseases 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000035168 lymphangiogenesis Effects 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (24)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910461395.8A CN110129446B (zh) | 2019-05-30 | 2019-05-30 | 用于人体her2基因扩增状态检测的组合套装 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910461395.8A CN110129446B (zh) | 2019-05-30 | 2019-05-30 | 用于人体her2基因扩增状态检测的组合套装 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110129446A true CN110129446A (zh) | 2019-08-16 |
CN110129446B CN110129446B (zh) | 2023-06-27 |
Family
ID=67582917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910461395.8A Active CN110129446B (zh) | 2019-05-30 | 2019-05-30 | 用于人体her2基因扩增状态检测的组合套装 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110129446B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102618646A (zh) * | 2012-03-30 | 2012-08-01 | 南方医科大学 | 一种基因拷贝数的定量检测方法 |
CN103205425A (zh) * | 2012-01-17 | 2013-07-17 | 北京万达因生物医学技术有限责任公司 | 抑制引物非特异性扩增的反义干扰寡核苷酸 |
CN105112522A (zh) * | 2015-08-21 | 2015-12-02 | 北京鑫诺美迪基因检测技术有限公司 | Her2基因扩增的检测引物组及试剂盒 |
CN107365867A (zh) * | 2017-09-04 | 2017-11-21 | 天津华大医学检验所有限公司 | 一种用于检测基因组目标区域的引物组合物及其应用 |
CN107739760A (zh) * | 2017-11-16 | 2018-02-27 | 杭州迪安医学检验中心有限公司 | 一种用于her‑2基因拷贝数扩增检测的核酸序列、试剂盒及其应用 |
CN108504742A (zh) * | 2018-06-25 | 2018-09-07 | 北京爱普拜生物技术有限公司 | 一种基于数字pcr技术检测her-2基因拷贝数变异的试剂盒及方法 |
-
2019
- 2019-05-30 CN CN201910461395.8A patent/CN110129446B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103205425A (zh) * | 2012-01-17 | 2013-07-17 | 北京万达因生物医学技术有限责任公司 | 抑制引物非特异性扩增的反义干扰寡核苷酸 |
CN102618646A (zh) * | 2012-03-30 | 2012-08-01 | 南方医科大学 | 一种基因拷贝数的定量检测方法 |
CN105112522A (zh) * | 2015-08-21 | 2015-12-02 | 北京鑫诺美迪基因检测技术有限公司 | Her2基因扩增的检测引物组及试剂盒 |
CN107365867A (zh) * | 2017-09-04 | 2017-11-21 | 天津华大医学检验所有限公司 | 一种用于检测基因组目标区域的引物组合物及其应用 |
CN107739760A (zh) * | 2017-11-16 | 2018-02-27 | 杭州迪安医学检验中心有限公司 | 一种用于her‑2基因拷贝数扩增检测的核酸序列、试剂盒及其应用 |
CN108504742A (zh) * | 2018-06-25 | 2018-09-07 | 北京爱普拜生物技术有限公司 | 一种基于数字pcr技术检测her-2基因拷贝数变异的试剂盒及方法 |
Also Published As
Publication number | Publication date |
---|---|
CN110129446B (zh) | 2023-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1272668B1 (en) | Methods, compositions and kits for the detection and monitoring of breast cancer | |
CN101875972B (zh) | Kras基因突变的快速检测 | |
CN103710460B (zh) | 定量检测egfr基因突变的试剂盒及其用途 | |
AU2005250479B2 (en) | Diagnosing or predicting the course of breast cancer | |
WO2003028531A2 (en) | Detection of tumor rna in plasma and serum | |
CN104805206B (zh) | 检测tert基因启动子突变的试剂盒及其检测方法 | |
CN109735623B (zh) | 一种结直肠癌生物标志物 | |
CA2617693A1 (en) | Composition and method for determination of ck19 expression | |
CN110438223A (zh) | 检测Kras基因点突变的引物、探针及其试剂盒与检测方法 | |
CN111424097B (zh) | 用于开发胃癌诊断产品的分子标志物及应用 | |
US8163524B2 (en) | Comparative analysis of extracellular RNA species | |
CN101875971A (zh) | Braf基因突变的快速检测 | |
CN109371124A (zh) | miR-6802-3p在绝经后妇女骨质疏松症早期诊断中的应用 | |
CN101875970A (zh) | Apc基因突变的快速检测 | |
JP2013523178A (ja) | Krasプライマーおよびプローブ | |
CN110129446A (zh) | 用于人体her2基因扩增状态检测的组合套装 | |
US20070042368A1 (en) | Detection and monitoring of lung cancer | |
KR101381894B1 (ko) | 위암의 림프절 전이 진단 마커로서의 혈청 miRNA | |
CN113122629B (zh) | 用于基因突变检测的发夹式扩增阻断法的引物和探针及其应用 | |
CN114410795A (zh) | 基于miRNA特征标记的肝癌早期检测 | |
EP1092782A2 (en) | Genetic screening method and genetic screening apparatus | |
CN102021169A (zh) | 一种血清/血浆miRNA组合物及其应用 | |
US11021756B2 (en) | MiRNA markers for the diagnosis of osteosarcoma | |
Anderson et al. | Reliable gene expression measurements from fine needle aspirates of pancreatic tumors: effect of amplicon length and quality assessment | |
CN107029238A (zh) | Linc01094在诊治缺血性脑卒中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230915 Address after: No. 8 Anhe Second Road, High tech Zone, Chengdu, Sichuan Province, 611730 Patentee after: MACCURA MEDICAL ELECTRONICS Co.,Ltd. Address before: 100085 106, area B, Zhongguancun biomedical park, No.5 Kaifa Road, Haidian District, Beijing Patentee before: Beijing Da Microbiology Technology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231212 Address after: 611731, 16 Chengdu, hi tech Zone, Sichuan, China Patentee after: MACCURA BIOTECHNOLOGY Co.,Ltd. Address before: No. 8 Anhe Second Road, High tech Zone, Chengdu, Sichuan Province, 611730 Patentee before: MACCURA MEDICAL ELECTRONICS Co.,Ltd. |
|
TR01 | Transfer of patent right |